{
    "Trade/Device Name(s)": [
        "MammaPrint"
    ],
    "Submitter Information": "Agendia BV",
    "510(k) Number": "K070675",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062694"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "May 31, 2007",
    "Summary Letter Received Date": "June 4, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [
        "Breast cancer tissue"
    ],
    "Specimen Container(s)": [
        "RNAlater",
        "Frozen tissue sections"
    ],
    "Instrument(s)/Platform(s)": [
        "MammaPrint microarray"
    ],
    "Method(s)/Technology(ies)": [
        "Gene expression analysis",
        "Microarray"
    ],
    "Methodologies": [
        "Gene expression profiling",
        "Microarray analysis"
    ],
    "Submission Type(s)": [
        "Test",
        "Service"
    ],
    "Document Summary": "FDA 510(k) summary for Agendia MammaPrint gene expression profiling test system for breast cancer prognosis using microarray technology.",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test service using gene expression profile of fresh breast cancer tissue samples to assess risk for distant metastasis in patients under 61 years, Stage I/II, tumor size \u22645.0 cm, lymph node negative, for prognostic use by physicians with other clinicopathological factors.",
    "fda_folder": "Immunology"
}